Viking Therapeutics (VKTX) shares advanced 10.91% following disappointing results from Novo Nordisk's REDEFINE 4 trial, which failed to demonstrate non-inferiority for its obesity treatment CagriSema against Eli Lilly's tirzepatide. The trial data showed CagriSema achieved 20.2% weight loss compared to 23.6% for tirzepatide, a significant gap in the competitive obesity therapeutics market where efficacy margins are closely monitored by investors and healthcare providers.
The market response reflects investor optimism regarding Viking's VK2735, a dual GLP-1/GIP agonist candidate entering Phase 3 trials in the third quarter of 2026. Unlike existing competitors, VK2735 offers both injectable and oral formulations, a dual-delivery approach that addresses different patient preferences and treatment scenarios. This differentiation in the delivery mechanism may provide a competitive advantage as the obesity drug market expands, particularly given the recent setbacks for alternative candidates.
The obesity therapeutics space remains highly competitive, with multiple pharmaceutical companies advancing treatments to capture market share in a segment demonstrating strong patient demand and substantial commercial potential. Viking's progression toward late-stage trials positions the company as a notable participant in the ongoing clinical and commercial developments within this therapeutic area.